The Future of Precision Medicine Depends on Data, Infrastructure, and Incentives: Axia Medicine is Unlocking All Three

Published by Axia Medicine | April 2025

Precision Medicine promised something transformative: better treatments, earlier diagnoses, and more accurate care, all tailored to the individual.

Decades later, this promise remains unfulfilled. Not because we lack technology. Not because we lack data.

Precision Medicine is still far from realized because of incomplete data, missing infrastructure and misaligned incentives.

At Axia Medicine, we’re fixing all three.

1. The Data Problem: Fragmented, Exploited, Incomplete

Today, most patient data is scattered across siloed systems: Electronic Health Records, lab testing facilities, wearables and apps, online questionnaires and social media… Worse, much of it is inaccessible to the patients themselves.

Some companies built their business models on patient data abandonment: they survive by betting that people will forget they even gave up their data. We’ve seen the results: the collapse of platforms like 23andMe, which collected genetic data under the pretense of “insights” only to turn that data into an asset class, now being auctioned to the highest bidder.

Axia believes something radical:
Your data should work for you, for the benefit of your health and your family’s.

Our platform makes it possible for individuals, especially those with rare or syndromic conditions, to collect and unify their health data across systems and share it, on their terms, with the providers, researchers, and services that matter to them. No brokers. No backdoors. No exploitation.

2. The Infrastructure Problem: Built for Brokers, Not People

We hear a lot about “federated” data platforms, especially in public health. But most so-called federated platforms are anything but: they’re centralized systems with poor transparency, designed to extract value rather than create trust.

At Axia, we’ve built a patient-centric infrastructure from the ground up. That means:

• Granular consent: patients control how, when, and with whom their data is shared

• Zero trust architecture: no third party sees the data unless explicitly authorized by the patient

• Interoperability by design: our proprietary platform makes multimodal data accessible for population studies, in compliance with international industry standards

• Sovereign data protection: data owners retain control of their data, stored within their original country.

Our infrastructure isn’t built for short-term recruitment or “data mining”: it’s built for longitudinal engagement, population-scale real-world evidence, to build a future where patients are not simple spectators of biomedical innovation, but active participants.

With Axia, Precision Medicine is true Participatory Medicine.

3. The Incentive Problem: Patients Give, Everyone Else Gets

In today’s system, millions of patients donate data and a handful of companies extract value.

Patients get a report, or worse, nothing at all.

This has created a fragile, extractive model where trust breaks down and patients disengage. And that breakdown is why AI tools fail, clinical trials struggle to recruit, and drug discovery slows to a crawl.

Axia flips the model:

• Patients are compensated for sharing their data - they decode if, how and when

• They receive access to tailored services, insights, and research opportunities:

• They choose what matters - money, information, impact - and opt in accordingly

With Axia, industry works at the service of patients, not vice versa. By aligning incentives between patients and the industry, we build something stronger than consent: mutual, compounded, long-term value.

4. The Patient-Centric Alternative Is Already Here

We don’t need to imagine what this future looks like, we’ve started building it.

We’re in conversation with pharma, CROs, and diagnostics partners who need consented, real-world, multiomic datasets that don't exist anywhere else. And we’re doing it all while putting choice, transparency, and benefit in the hands of the individual.

Whether it’s sharing genomic data with a precision oncology trial, getting matched to mental health services, or participating in research that reflects their community, patients now have a say, and a stake.

5. The Outcome: Axia creates Real Lives’ Evidence to accelerate Health AI and Maximise Health Equity

Too many Health AI models fail because they rely on incomplete or biased data. Too many research initiatives fail because they treat participation as transactional. Too many health equity programs fail because they never fix the infrastructure.

Axia fixes the foundation:

• for Health AI: we provide diverse, longitudinal, consented datasets that reflect real lives - Real Life Evidence

• for Researchers: we eliminate the bottlenecks and minimise legal risks of recruitment, follow-up and data access

• for Patients: we offer participation with purpose, making industry work for YOUR benefit, finally aligning incentives with outcomes

This is the only sustainable path forward: a data infrastructure that respects the patient, serves the industry, and unlocks the next generation of breakthroughs.

Precision Medicine Starts with the Patient

The Axia team has been working on the frontline of Precision Medicine for a very long time, learning from patients and organisations around the world.

Each country had different challenges, but one thing was always true:

Precision Medicine starts with the patient.

We’ve seen what works and what doesn’t. That’s why we’re not here to build another data product. We’re here to build a new health data economy, one that puts power in the hands of the people who’ve never had it: patients.

The future of Precision Medicine depends on data, infrastructure, and incentives. Axia is rebuilding all three.

And we are just getting started.

Learn more about Axia’s team and Guiding Principles.

Our Industry Network keeps growing. Reach out to explore partnerships or join our pilot program.